|
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) |
Mar 2019 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic Syndromes Treatment (PDQ®): Patient Version |
Mar 2019 |
National Cancer Institute |
Myelodysplastic Syndromes (MDS) |
|
Clonal Hematopoiesis and therapy related MDS/AML |
Mar 2019 |
Best Practice & Research. Clinical Heamatology |
Myelodysplastic Syndromes (MDS) |
|
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes |
Mar 2019 |
Clin Lymphoma Myeloma Leuk |
Myelodysplastic Syndromes (MDS) |
|
Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. |
Feb 2019 |
Cancer Med |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Rethinking clinical trial endpoints in myelodysplastic syndromes. |
Jan 2019 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
|
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes |
Jan 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. |
Jan 2019 |
Bone Marrow Transplant |
Myelodysplastic Syndromes (MDS) |
|
Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. |
Jan 2019 |
Leuk Lymphoma. |
Myelodysplastic Syndromes (MDS) |
|
Calculator-free point-of-care prognostication in myelodysplastic syndromes. |
Jan 2019 |
Am J Hematol |
Myelodysplastic Syndromes (MDS) |
